Patents Examined by Janet L. Epps
  • RNA ligand-displaying exosomes for specific delivery of therapeutics to cell by RNA nanotechnology
    Patent number: 10590417
    Abstract: Disclosed herein are compositions comprising extracellular vesicles, such as exosomes, displaying an RNA nanoparticle on its surface. The RNA nanoparticle can target the extracellular vesicle to a given cell via a targeting moiety. The extracellular vesicle can also comprise a functional moiety, which can be used in treatment or diagnostics.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: March 17, 2020
    Assignee: Ohio State Innovation Foundation
    Inventors: Peixuan Guo, Fengmei Pi, Hui Li, Shaoying Wang
  • Selective cell therapy for the treatment of renal failure
    Patent number: 10590391
    Abstract: Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein the cells have been expanded in vitro. The kidney cells preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods of producing an isolated population of EPO producing cells are also provided, and methods of treating a kidney disease resulting in decreased EPO production in a patient in need thereof are provided, including administering the population to the patient, whereby the cells express EPO in vivo in an oxygen tension-dependent manner.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: March 17, 2020
    Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCES
    Inventors: Anthony Atala, James J. Yoo
  • Nucleic acid products and methods of administration thereof
    Patent number: 10576167
    Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: March 3, 2020
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
    Patent number: 10550183
    Abstract: The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: February 4, 2020
    Assignee: National University of Singapore
    Inventors: Yi Tian Png, Natasha Vinanica, Takahiro Kamiya, Dario Campana
  • Oncolytic adenovirus encoding a therapeutic protein or active fragment
    Patent number: 10548929
    Abstract: The present disclosure provides a oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a membrane anchored anti-CD3 antibody or a binding fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: February 4, 2020
    Assignee: PSIOXUS THERAPEUTICS LIMITED
    Inventors: Brian Robert Champion, Alice Claire Noel Brown
  • Polyplex of double-stranded RNA and polymeric conjugate
    Patent number: 10543232
    Abstract: A polyplex of a double stranded RNA (dsRNA) and a polymeric conjugate consists of a linear polyethyleneimine (PEI) covalently linked to one or more polyethylene glycol (PEG) moieties. Each PEG moiety is conjugated via a linker to a targeting moiety capable of binding to a cancer antigen. Exemplary cancer antigens include epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2) and prostate surface membrane antigen (PSMA).
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: January 28, 2020
    Assignee: TargImmune Therapeutics AG
    Inventors: Alex Levitzki, Salim Joubran, Alexei Shir, Maya Zigler, Alaa Talhami, Yael Langut
  • Adsorbent composition and use thereof
    Patent number: 10537887
    Abstract: The present invention provides a novel adsorbent composition for recovering biomolecules from a fluid. The composition comprises positively and negatively charged microparticles in the form of ground particles. The adsorbent is particularly useful for purification of biomolecules from the cell culture.
    Type: Grant
    Filed: August 25, 2014
    Date of Patent: January 21, 2020
    Assignees: BOEHRINGER INGELHEIM RCV & GMBH CO KG, SANDOZ AG
    Inventors: Rainer Hahn, Alois Jungbauer, Alexandru Trefilov, Moritz Imendoerffer
  • Targeted and modular exosome loading system
    Patent number: 10538570
    Abstract: Disclosed are exosomes that include a packaging protein and a cargo RNA in which the packaging protein binds specifically to the cargo RNA. The packaging protein is a fusion protein that includes an RNA-binding domain and an exosome-targeting domain. The cargo RNA includes an RNA-motif that the RNA-binding domain of the fusion protein binds specifically such that the cargo RNA is packaged in the lumen of the exosomes.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: January 21, 2020
    Assignee: Northwestern University
    Inventors: Joshua N. Leonard, Michelle E. Hung
  • Systems and methods for preclinical models of metastases
    Patent number: 10525148
    Abstract: Embodiments of the invention provide methods of creating clinical models for different forms of metastatic cancer. The methods may include obtaining samples from subjects with metastatic cancer, determining an allelic status of one or more markers in the samples (e.g., creating a molecular profile of the subject's cancer), and using model organisms with subject-derived xenografts for treatment selection.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: January 7, 2020
    Assignee: The Translational Genomics Research Institute
    Inventor: Bodour Salhia
  • Gene delivery system using polymer network
    Patent number: 10517963
    Abstract: Provided is a gene delivery including a polymer network formed by binding phenylboronic acid, sugar, and a low-molecular weight branched polymer. The gene delivery may be stably maintained in vivo and efficiently deliver a gene specifically to cancer cells, such that the gene delivery system may be usefully used as a gene delivery system for chemotherapy.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: December 31, 2019
    Assignees: Institute for Basic Science, POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Won Jong Kim, Jinhwan Kim
  • Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers
    Patent number: 10517822
    Abstract: Nanoscale coordination polymer nanoparticles for the co-delivery of multiple therapeutic agents are described. The multiple therapeutic agents can include a combination of different chemotherapeutic agents, a combination of one or more chemotherapeutic agents and one or more nucleic acids, such as small interfering RNA (siRNA) or microRNA, a combination of one or more chemotherapeutic agents and a photosensitizer (i.e., for use in photodynamic therapy), or a plurality of different siRNAs. Pharmaceutical formulations including the nanoparticles, methods of using the nanoparticles to treat cancer, and methods of making the nanoparticles are also described.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: December 31, 2019
    Assignees: The University of Chicago, The University of North Carolina at Chapel Hill
    Inventors: Wenbin Lin, Chunbai He, Demin Liu
  • Cationic lipid
    Patent number: 10500158
    Abstract: The present invention provides a cationic lipid represented by the formula (I) wherein R1 and R2 each represents alkyl having 8 to 24 carbon atoms or the like; R3 represents a hydrogen atom, alkyl having 1 to 3 carbon atoms, the formula (A) wherein R4 and R5 each represents a hydrogen atom or the like, and n3 represents an integer from 2 to 6, or the formula (B) wherein R6 and R7 each represents a hydrogen atom or the like, and n4 represents an integer from 1 to 6; n1 represents an integer from 0 to 4; and n2 represents an integer from 1 to 4, provided that the case where n1 is 0 and n2 is 1 is excluded, and a composition which contains the cationic lipid and a nucleic acid, or the like.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: December 10, 2019
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Shintaro Hosoe, Tomoyuki Naoi
  • Compositions and methods for treating cancer with anti-CD19 immunotherapy
    Patent number: 10501539
    Abstract: Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: December 10, 2019
    Assignees: Lentigen Technology Inc., The U.S.A., as Represented By The Secretary, Department of Health and Human Services
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Modified silk films containing glycerol
    Patent number: 10493179
    Abstract: The present invention provides for compositions and methods for preparing aqueous insoluble, ductile, flexible silk fibroin films. The silk films comprise silk fibroin and about 10% to about 50% (w/w) glycerol, and are prepared by entirely aqueous processes. The ductile silk film may be further treated by extracting the glycerol from and re-drying the silk film. Active agents may be embedded in or deposited on the glycerol modified silk film for a variety of medical applications. The films may be shaped into 3-dimensional structures, or placed on support surfaces as labels or coatings. The glycerol modified silk films of the present invention are useful in variety of applications such as tissue engineering, medical devices or implants, drug delivery, and edible pharmaceutical or food labels.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: December 3, 2019
    Assignee: Trustees of Tufts College
    Inventors: Shenzhou Lu, Xiaoqin Wang, Fiorenzo Omenetto, David L. Kaplan
  • Ligand binding molecules and uses thereof
    Patent number: 10494617
    Abstract: The present invention is directed to polynucleotides that encode VEGFR-3 ligand binding molecules and uses thereof to modulate angiogenesis and/or lymphangiogenesis. A glycosylation sequon of wildtype VEGFR-3 has been modified to eliminate glycosylation in the encoded ligand binding molecules.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: December 3, 2019
    Assignee: VEGENICS PTY LIMITED
    Inventors: Michael Gerometta, Timothy Adams
  • RNA formulation for immunotherapy
    Patent number: 10485884
    Abstract: The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: November 26, 2019
    Inventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Mustafa Diken, Daniel Fritz, Martin Meng, Lena Mareen Kranz, Kerstin Reuter
  • Immunisation of large mammals with low doses of RNA
    Patent number: 10487332
    Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: November 26, 2019
    Assignee: GlaxoSmithKline Biologicals SA
    Inventor: Andrew Geall
  • Irradiated biodegradable polymer microparticles
    Patent number: 10485761
    Abstract: In one aspect, the present invention provides sterile microparticle compositions comprising biodegradable microparticles, which comprise at least one biodegradable polymer. In other aspects, the present invention provides methods of making and using such compositions as well as articles of manufacture and kits containing the same.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: November 26, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventors: Derek O'Hagan, Manmohan Singh, Siddhartha Jain, Padma Malyala
  • Poly(amine-co-ester) nanoparticles and methods of use thereof
    Patent number: 10465042
    Abstract: Polymers including poly(amine-co-ester), poly(amine-co-amide), or a combination thereof, and nanoparticles, particularly solid core nanoparticles, formed therefrom are provided. Solid core nanoparticles fabricated from hydrophobic polymers often require the presence of cationic complexing agents to stabilize negatively charged active agents such as siRNA. However, complexing agents are optional in the disclosed formulations because the nanoparticles contain cationic amines to stabilize negatively charged nucleic acids and hydrophobic domains to condense the nucleic acid into the core of the formed nanoparticles, thus improving encapsulation efficiency. This increase in nucleic acid loading allows the disclosed solid core nanoparticles to deliver more nucleic acid per cell without increasing total polymer delivered, further reducing cytotoxicity.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: November 5, 2019
    Assignee: YALE UNIVERSITY
    Inventors: Jiajia Cui, Junwei Zhang, W. Mark Saltzman
  • Liposomal adjuvant compositions
    Patent number: 10456459
    Abstract: The invention provides a liposomal adjuvant composition comprising an external membrane and an internal compartment, the external membrane comprising: a quaternary ammonium compound; a sterol; a phospholipid; and a glycolipid. Vaccine compositions comprising the liposomal adjuvant of the instant invention are also provided.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: October 29, 2019
    Assignee: Zoetis Services LLC
    Inventors: Paul Joseph Dominowski, Duncan Mwangi, Sharath K. Rai, Dennis L. Foss, Traci K. Godbee, Laurel Mary Sly, Suman Mahan, Shaunak Vora